Clinical trial
A Phase I/II Trial to Evaluate the Tolerability, Anti-CMV Activity and Pharmacokinetics of 1263W94 Following Multiple Oral Administration of Escalating Doses in HIV-Infected Patients With Asymptomatic CMV Shedding
NCT00002373 is registered in ClinicalTrials.gov with Glaxo Wellcome as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Trial to Evaluate the Tolerability, Anti-CMV Activity and Pharmacokinetics of 1263W94 Following Multiple Oral Administration of Escalating Doses in HIV-Infected Patients With Asymptomatic CMV Shedding
- Lead sponsor
- Glaxo Wellcome
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- Not reported
- Completion date
- Not reported
- Enrollment
- 56
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.